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Abstract
Aldose reductase (AR) is an NADPH-dependent reductase, which acts on a variety of hydrophilic as well as
hydrophobic aldehydes. It is currently defined as the first enzyme in the so-called polyol pathway, in which glucose is
transformed into sorbitol by AR and then to fructose by an NAD+-dependent dehydrogenase. An exaggerated flux of
glucose through the polyol pathway (as can occur in diabetes) with the subsequent accumulation of sorbitol, was
originally proposed as the basic event in the aethiology of secondary diabetic complications. For decades this has
meant targeting the enzyme for a specific and strong inhibition. However, the ability of AR to reduce toxic alkenals
and alkanals, which are products of oxidative stress, poses the question of whether AR might be better classified as
a detoxifying enzyme, thus raising doubts as to the unequivocal advantages of inhibiting the enzyme. This paper
provides evidence of the possibility for an effective intervention on AR activity through an intra-site differential
inhibition. Examples of a new generation of aldose reductase “differential” inhibitors (ARDIs) are presented, which
can preferentially inhibit the reduction of either hydrophilic or hydrophobic substrates. Some selected inhibitors are
shown to preferentially inhibit enzyme activity on glucose or glyceraldehyde and 3-glutathionyl-4-hydroxy-nonanal,
but are less effective in reducing 4-hydroxy-2-nonenal. We question the efficacy of D, L-glyceraldehyde, the substrate
commonly used in in vitro inhibition AR studies, as an in vitro reference AR substrate when the aim of the
investigation is to impair glucose reduction.
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Introduction
Aldose reductase (AR) is an NADPH-dependent [1] aldo-keto
reductase (EC 1.1.1.21) that catalyzes the reduction of a
variety of hydrophobic as well as hydrophilic aldehydes (for
reviews, see 2,3). The enzyme is considered as part of the so-
called polyol pathway in which glucose is first reduced by AR to
sorbitol, which is then oxidized to fructose by a NAD+
dependent sorbitol dehydrogenase [4]. An increased flux of
glucose through the polyol pathway in hyperglycemic
conditions has been considered to cause tissue damage
through different mechanisms, including an osmotic imbalance
due to sorbitol accumulation [5], an imbalance of the pyridine
nucleotide redox status, which decreases the antioxidant cell
ability [6], and an increase in the advanced glycated end
products [7-9]. All these cell-damaging processes can cause
diabetic complications, such as nephropathies, retinopathies,
peripheral neuropathies and cataract. Consequently, AR has
been considered as a target enzyme to develop drugs that act
as AR inhibitors (ARIs), which are thus able to prevent the
onset of diabetic complications and to control their evolution.
Recently, AR has been shown to be involved in ischemic and
inflammatory processes [10-12] and to be overexpressed in
some types of cancer [10,13]. This led to the increased interest
in ARIs as anti-inflammatory agents [14]. Over the last three or
four decades a number of ARIs have been discovered and then
proposed as potential therapeutic tools. Despite the in vitro
efficiency of ARIs, their use as drugs to antagonize diabetic
complications has not been very successful (to the best of our
knowledge India and Japan are the only countries where an
Epalrestat-based drug is distributed). This is possibly because
of an insufficient bioavailability [15,16] and/or a possible
modulation in the AR susceptibility to inhibition exerted by S-
thiolation phenomena [17-20]. Moreover, some ARIs have
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been withdrawn due to the appearance of severe secondary
effects in preclinical and/or clinical trials [21,22]. These adverse
effects may be related to the impairment of some AR functions
upon ARI treatment. In fact one of the functions of AR is its
ability to reduce toxic aldehydes, such as 4-hydroxy-2,3-
nonenal (HNE), which are end products of lipid peroxidation
[23], and whose cytotoxicity appears to be lower when they
have been reduced. In addition, the ability of AR to reduce the
glutathionyl-HNE adduct (GS-HNE) [24] represents a link
between AR activity and the cell response to the oxidative
signaling cascade [14,25]. The enzyme may also act as an
osmoregulatory device [26,27] and plays an important role in
the synthesis of fructose [4], tetrahydrobiopterin [28,29] and in
the metabolism of corticosteroids [30-32].
All these aspects raise doubt for an a priori overall
advantage in inhibiting the enzyme.
The possibility of selectively intervening on the enzyme’s
catalytic action on specific substrates, such as glucose, is a
clear benefit as it leaves the reduction of damaging molecules
such as HNE unaffected or partially affected. These aldose
reductase differential inhibitors (ARDIs) have the potential to
target AR in strict relation to the substrate that the enzyme is
working on. This means that damaging events (i.e. sorbitol and
GS-DHN generation) could be blocked (fully or partially)
without affecting the detoxification ability of the enzyme (i.e.
HNE reduction).
The fact that hydrophilic molecules, such as GAL, glycol
aldehyde or L-threose, and hydrophobic molecules, such as
HNE, are similarly effective as AR substrates [33-35], suggests
a rather poor selectivity of the enzyme, apparently permissive
to the entrance of any kind of aldehydic substrate. However
looking inside the same class of hydrophobic [34] as well as
hydrophilic [33,36] molecules, it appears that AR is not simply a
permissive enzyme, being able to discriminate different
substrates among the same class. In any case, the ability of
sugar molecules and hydrophobic aldehydes to interact with
AR with the same or similar efficiency, would suggest that
these molecules may interact with the enzyme following
different interactive pathways.
The peculiar ability of AR to intervene both on hydrophilic
and hydrophobic substrates without being a permissive
enzyme opens the possibility to identify ARDIs to be developed
as possible useful instruments to modulate AR activity. The
possibility of inhibiting AR while acting on aldoses but not on
toxic aldehydes, previously recommended as a valuable task to
be reached [37], was strengthened through an in silico
approach [38] in which, considering an inhibitor-inducible cavity
region located close to the active AR site [39], a number of AR
inhibitory molecules were designed, which still need to be
tested in terms of how well they are able to differentially inhibit
the enzyme.
In this paper evidence is presented for an effective
intervention on AR activity through an intra-site differential
inhibition. Our data, which represent the results of what we
believe is the first experimental attempt to use ARDIs in AR
inhibition studies, suggest that searching for ARDIs may be a
suitable approach.
Materials and Methods
Materials
NADPH, D, L-glyceraldehyde (GAL), D-glucose, dithiothreitol
(DTT), sodium EDTA, were purchased from Sigma-Aldrich Italy
(Milano, Italy); HNE dimethylacetal was purchased from Enzo
Life Science Inc. (New York, USA) and the free aldehyde was
obtained with the addition of 1 mM HCl; GS-HNE came from
Cayman Europe (Tallin, Estonia). All inorganic chemicals (from
BDH, London, UK) were of reagent grade.
AR inhibitors
Molecules tested as AR inhibitors are identified by code
numbers in bold. The structures of the compounds tested as
AR inhibitors are reported in Tables S1 and S2.
The pyrido(1,2-a) pyrimidinones 1-8 [40], oxadiazole 9 [41],
naphtho(1,2-d) isothiazole10 [42], (1,2,4) triazino(4,3-a)
benzimidazoles 11,12 and the benzimidazole 13 [43],
benzisotiazoles 14-16 [44], and 17 [45] were synthesized as
described in the references. The pyrazolo(1,5-a)pyrimidines
18-20 and amides 21-25 were synthesized as reported in the
Protocol S1. D gluconamide (26), D-lactamide (27), Quercetin
(28) and Sorbinil (29) came from Sigma-Aldrich Italy. Epalrestat
(30) was from Haorui Pharma-Chem Inc., NJ, USA.
AR assay and purification
If not otherwise specified AR activity was determined at 37°C
using 4.7 mM D, L-GAL as a substrate in 0.25 M sodium
phosphate buffer pH 6.8 containing 0.38 M ammonium sulfate,
0.5 mM EDTA, and 0.2 mM NADPH. AR was purified from
bovine lens to electrophoretic homogeneity as described [46].
The final enzyme preparation displayed a specific activity of 1.2
U/mg. One unit of enzyme activity is the amount of enzyme that
catalyzes the oxidation of 1 µmol of NADPH/min under the
above-mentioned conditions. The kcat values were obtained on
the basis of a molecular weight of AR of 34 KDa. The purified
enzyme was stored at 4°C in a 10 mM sodium phosphate
buffer pH 7.0 supplemented by 2 mM dithiothreitol and was
extensively dialyzed against a 10 mM sodium phosphate buffer
pH 7.0 before use.
The nominal concentrations of HNE and GS-HNE solutions
used as substrates of AR were determined through a
colorimetric assay [47]. These values were confirmed by the
total decrease in absorbance at 340 nm measured, in the
presence of 0.2 mM NADPH, when HNE and GS-HNE were
incubated in the presence of 8 and 150 mU of AR, respectively
(Figure S1). When testing inhibitors that require DMSO to be
solubilized, the same concentration of DMSO (0.7% v/v), was
used in the assays both in the presence and absence of the
inhibitors.
Other methods
Protein concentration was determined according to Bradford
[48] using bovine serum albumin as the standard.
Aldose Reductase Differential Inhibition
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Results and Discussion
GAL and HNE used as substrates for AR displayed a very
similar kinetic behaviour. As shown in Figure 1 the double
reciprocal plots for the reduction of the two substrates by the
same purified enzyme preparation are almost superimposable
showing kcat and KM for GAL and HNE of 47 ± 3 and 48 ±1 min-1
and 39 ± 4 and 37 ± 1 µM, respectively.
The KM for GAL is in line with previously reported data for AR
from different sources, including the bovine lens enzyme
[24,49-53]. Similarly, the KM measured for HNE is reasonably
close to the one measured on human skeletal muscle (22 µM)
and human placental recombinant (28 ± 9 µM) enzymes
[34,35]. Nevertheless the KM measured for HNE appears
approximately five fold higher than the values reported for the
AR from bovine tissues, namely the lens (8.8±0.9 µM) and the
heart (7 ±2 µM) [24,52]. In addition to the more acidic assay
conditions (pH 6.0 rather than 6.8) adopted in previous
measurements, which, however, were not responsible for the
observed difference (Figure S2), it may be worth considering
the potential of HNE to inactivate AR [52,54]. In fact, even
though NADP+ has been reported to exert protection [52,54],
enzyme inactivation may still occur to some extent while the
enzyme is acting, especially at relatively high concentrations of
HNE. This is evident by applying the Selwyn test [55] to the AR
catalyzed reaction performed both at different concentrations of
HNE (from 50 to 220 µM) and at different concentrations of the
enzyme (from 3.5 to 8.8 mU) (Figure S3). The underestimation
of the reaction rate occurring at high substrate concentrations
may lead to an overestimation of the apparent affinity between
HNE and AR. Thus, in this study the assays were performed in
Figure 1.  Double reciprocal plots for reduction of GAL,
HNE and GS-HNE by bovine lens AR.  Double reciprocal
plots of initial rate measurements using of GAL (diamonds),
HNE (squares) and GS-HNE (circles) as substrates. The
assays were performed in standard conditions using 8 mU of
purified AR. Error bars represent the standard deviations from
at least three independent measurements.
doi: 10.1371/journal.pone.0074076.g001
the presence of 8 mU of AR using HNE concentrations that
were never above 0.11 mM, i.e. a safe limit according to the
Selwyn test. The insertion of a hydrophilic moiety into HNE, as
it occurs for the GS-HNE adduct, determined, differently from
that observed for other alkanals and alkenals [51], a modest
decrease of the kcat (41 ± 2 min-1) with approximately a 3 fold
increase of the KM (105 ± 6µM) with respect to the parameters
measured for HNE (Figure 1). However, in the case of GS-
HNE, a stable intramolecular hemiacetal may be formed and
this could reduce the concentration of the free carbonyl with an
increase in the apparent KM. The occurrence of the stable
hemiacetal is consistent with the higher amount of AR required
for GS-HNE titration with respect to HNE (Figure S1).
Concerning the kcat value, it appears only slightly changed
compared to HNE as a result of the insertion of the glutathionyl
moiety into HNE. Note that the value of KM for GS-HNE was
approximately three fold higher than the previously reported
result for the bovine lens enzyme [24].
The similarity of the kinetic parameters (KM and kcat)
displayed by GAL and HNE represents an ideal condition to
compare the ability of different molecules to behave as ARDIs.
Thus, the susceptibility of AR to the inhibition exerted by a
series of compounds (including some well-known ARIs) was
tested at various inhibitor concentrations, using both GAL and
HNE as substrates. The results of this screening (Figure 2) are
expressed as ”GAL/HNE differential inhibition”, i.e. the
difference between the percentage inhibition observed using
GAL as a substrate and the percentage inhibition observed
using HNE as a substrate. This differential inhibition was
calculated at the concentration of the inhibitor leading to 50%
inhibition or, when 50% inhibition was not reached, at the
maximal concentration tested. The data indicate that the
purified bovine lens AR may vary in susceptibility to inhibition
depending on the substrate the enzyme is working on. This is a
case where there is a preferential inhibition of both GAL and
HNE reduction, but also where no preferential inhibitory action
against the reduction of a specific substrate takes place. Thus,
differential inhibition values are observed, ranging from
approximately +40% (i.e. HNE reduction is favored), exerted by
GAM and D-gluconamide (compounds 21 and 26,
respectively), to -25% (i.e. GAL reduction is favored), exerted
by compound 16. Despite the number of compounds tested, it
is difficult at this point to find a relationship between structure
and ARDI behavior, mainly because of the structural
heterogeneity as well as of the wide range of inhibitory power
of the compounds. In this regard, the available PDB data of AR
structures co-crystallized with very strong inhibitors are, as
such, less helpful in finding special structural requirements for
ARDIs than one would expect. In fact, they are lacking of the
most relevant information concerning the reciprocal influence
between the substrate and the inhibitor, both interacting with
the enzyme.
The not permissive feature of AR, mentioned above for
substrates (see Introduction), appears to be confirmed for
inhibitors of the same class as well. In fact, starting with GAM,
a variety of differential inhibitory effects was observed for
different aldonamides (compounds 21-27). Indeed, a
significantly lower value of ”GAL/HNE differential inhibition”
Aldose Reductase Differential Inhibition
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was observed (approximately 7%) when L-glyceramide
(compound 22) was used instead of the D-enantiomer
(compound 22, Figure 2).
Similar to what was observed for GAL, the reduction of GS-
HNE was also inhibited by GAM (IC50 of approximately 8 mM)
more efficiently than the HNE reduction (Figure 3). In the case
of glucose a differential inhibition glucose/HNE was observed
only at rather high concentrations of GAM (Figure 3).
However, the kinetic behavior of both glucose and GS-HNE
is very different from HNE (and consequently from GAL), which
must be taken into account when directly comparing the
differential inhibition data. In the case of glucose, for instance,
the concentration used in the assay (7 mM), which is the blood
concentration occurring in moderate hyperglycemic conditions,
led to sub-saturating conditions considering the rather high KM
value of AR for glucose (35 to 212 mM) [33,49,50,56-58]. A
similar situation may also take place with GS-HNE, which was
assayed at a substrate concentration very close to the KM
value.
These data clearly show the potential of a specific AR intra-
site differential inhibition. However, considering the differential
inhibition values and the inhibitor concentrations required for
GAM to exert inhibition (IC50 of approximately 10 mM with GAL
as substrate), we failed to target high differential intra-site
specificity and high inhibitory power at the same time.
The screening of molecules as potential ARDIs reported in
Figure 2 highlights various critical issues. The first concerns the
absolute values of inhibition exerted by the inhibitor on the
reduction of HNE. In this regard, compound 3 can be taken as
an example. Figure 4A reports the inhibition curves of
compound 3, obtained using GAL, HNE and glucose as
substrates. This molecule exhibited a GAL/HNE differential
inhibition of approximately 15%, a value that slightly increased
when glucose was used as a substrate rather than GAL.
However, this molecule cannot be defined as an ARDI. In fact it
inhibits the AR catalyzed reduction of all the tested substrates,
including HNE. In this respect compound 3 behaves, though
less efficiently, like the classical ARI Sorbinil (compound 29),
whose negligible GAL/HNE differential inhibition (Figure 2) was
accompanied by its potent inhibitory action on all the tested
substrates (Figure 4B).
Our study also highlights the fact that simply screening AR
inhibitors using GAL as substrate might be not sufficient to
select molecules, not only as potential ARDIs, but also as
ARIs, especially when the aim of the investigation is drug
development. Such screening is unavoidable as a preliminary
step before an in depth kinetic analysis of the selected
molecules, and is usually performed at rather high GAL
concentrations [59-62]. This leads to an underestimation of the
effectiveness of molecules which display a competitive or
mixed noncompetitive type of inhibition, especially, in the latter
case, when the component of the competitive action is
dominant. To overcome this limitation, when screening for the
selection of a potential inhibitor, it might be worth using glucose
Figure 2.  Differences in inhibition of AR depending on the nature of the substrate.  Bars indicate the difference between the
percentage inhibition observed using 0.11 mM GAL as substrate and the percentage inhibition using 0.11 mM HNE (differential
inhibition). The difference was calculated at the concentration of the inhibitor leading to a 50% inhibition of the reaction more
sensitive to the inhibitor (i.e. the reduction of GAL for compounds displaying a positive differential inhibition and the reduction HNE
for compounds displaying a negative differential inhibition) or at the maximal concentration tested if 50% inhibition was not reached.
Numbers on the bars refer either to the inhibitor concentration (µM) leading to 50% inhibition or to the maximal concentration (µM)
tested together with the corresponding percentage inhibition (in brackets) observed with the substrate that is more sensitive to the
inhibitor. Framed numbers (1 to 30) refer to the compounds tested as inhibitors.
doi: 10.1371/journal.pone.0074076.g002
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and possibly GS-HNE as substrates. In fact, unlike GAL or
HNE, the rather high KM values of glucose, would enable the
measurement of AR activity in sub-saturating conditions
without the possible limitations in the assay performance due to
low substrate levels, as might occur with GAL and HNE. It is
also evident that the use of glucose alone may be inadequate
for inhibition screening since an underestimation of the effect of
potential inhibitors with a marked prevalence of uncompetitive
action may occur. This might be the case, for instance, of D-
gluconamide (Figure 2) which, like GAM, exerts a significant
GAL/HNE differential inhibition, but appears to have no effect
on glucose reduction (data not shown).
The problem of underestimating the possible differential
inhibition ability of molecules is illustrated in Figure 5, which
reports the inhibition of the AR-dependent reduction of GAL,
HNE, D-glucose and GS-HNE by compounds 18 and 19. Both
compounds, which exert (see also Figure 2) an almost
negligible GAL/HNE differential inhibition, inhibit the reduction
Figure 3.  Effect of D-glyceramide as differential AR
inhibitor.  Percentage residual activity was determined at
various inhibitor concentrations using the following substrates:
0.11 mM of HNE (squares), GAL (diamonds), GS-HNE (circles)
or 7 mM D-glucose (triangles). Error bars represent the
standard deviations from at least three independent
measurements.
doi: 10.1371/journal.pone.0074076.g003
of glucose more efficiently than the reduction of HNE with a
glucose/HNE differential inhibition (evaluated at the highest
inhibitor concentration tested) of 24 ± 8 and 30 ± 5% for
compound 18, and compound 19, respectively. The observed
effect of compound 18 on glucose reduction can be ascribed to
a competitive inhibition, which is not revealed for both GAL and
HNE despite lowering the concentration of these substrates to
approximately the KM values (Figures S4 and S5). For
compound 19 the inhibitory action on glucose reduction is also
described by an inhibition model where the competitive action
dominates. The effects of compound 19 on the reduction of
GAL and, more distinctly, of HNE, are different and are
described by mixed and uncompetitive types of inhibition,
respectively. These data clearly indicate how the same inhibitor
may interact differentially with the enzyme depending on the
substrate used. Taking into account the absolute
concentrations at which these compounds are effective (μM
range), they appear to have the potential to be developed as
effective ARDIs.
Finally, as observed for GAM (Figure 3), both compounds 18
and 19 are also able to inhibit, to a different extent, the AR
catalyzed reduction of GS-HNE (Figure 5). In this case,
however, it is not easy to interpret the results in terms of the
inhibition model. This difficulty may be related to the special
structural features of GS-HNE, in which distinct hydrophilic and
hydrophobic moieties coexist. The presence of cyclic
hemiacetal stereo forms is also particular to this molecule,
which makes it difficult to clearly define the univocal assay
conditions in terms of substrate concentration.
In any event a differential inhibition between GS-HNE and
HNE is clearly possible. Considering the proposed action of the
GS-DHN (the reduction product of GS-HNE) as a pro-
inflammatory signal [14,25], we believe that these results
should be taken into consideration when searching for ARDIs
with anti-inflammatory activities.
Conclusions
We believe that the evidence presented here opens the way
for a new strategic approach to AR inhibition. The focus of this
work is not only on the features of potential ARDIs, but also on
the type of experimental approach to be adopted in looking for
ARIs. Indeed, by extending the same arguments used to
predict the potential of a differential inhibition between
substrates of different classes to different substrates of the
same class (i.e. aldoses), our results strongly suggest that
whenever the aim of the enzymological study on AR is the in
vivo inhibition of glucose reduction, then glucose itself, possibly
combined with GAL, should be used to screen the ARDI
potency in vitro. Similarly, when looking for molecules that can
differentially inhibit GS-HNE reduction with respect to HNE
reduction, GS-HNE itself should be used as a substrate of AR.
Finally, we firmly believe that it is time to switch from ARIs to
ARDIs. In fact, ARDIs could be valuable for investigating AR-
based useful/deleterious mechanisms and possibly for
clarifying the relative impact of the double-sided action of this
enzyme in experimental models. We also propose that a new
Aldose Reductase Differential Inhibition
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Figure 4.  Effect of some ARIs on the AR-catalyzed reduction of different substrates.  Percentage residual activity was
determined at the indicated inhibitor concentrations using the following as substrate: 0.11 mM of HNE (squares), GAL (diamonds),
GS-HNE (circles) or 7 mM D-glucose (triangles). Panel a and b refer to compound 3 and Sorbinil, respectively. Error bars represent
the standard deviations from at least three completely independent measurements including different enzyme preparations.
doi: 10.1371/journal.pone.0074076.g004
Figure 5.  Effect of compounds acting as differential AR inhibitors.  Percentage residual activity was determined at various
inhibitor concentrations using the following substrates: 0.11 mM HNE (squares), GAL (diamonds), GS-HNE (circles) or 7 mM D-
glucose (triangles). Panels a and b refer to compounds 18 and 19, respectively. Error bars represent the standard deviations from at
least three completely independent measurements including different enzyme preparations.
doi: 10.1371/journal.pone.0074076.g005
Aldose Reductase Differential Inhibition
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e74076
strategic approach to controlling enzyme activity against
diabetic complications and/or inflammation could be adopted.
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